Praxis Precision Medicines, Inc.
Business
Praxis Precision Medicines is a fully integrated central nervous system biopharmaceutical company developing therapies for neurological disorders characterized by neuronal excitation-inhibition imbalance, leveraging genetic insights from epilepsies. The company offers two proprietary platforms: Cerebrum™ for small-molecule precision therapies and Solidus™ for antisense oligonucleotide therapies, with four clinical-stage product candidates addressing essential tremor, developmental and epileptic encephalopathies, and common epilepsies. Praxis operates globally and pursues direct development and commercialization partnerships, including a co-development and licensing agreement with Tenacia Biotechnology for ulixacaltamide in Greater China.
Summary from 10-K filed 2026-02-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 0 | 9 | 2 | 0 | — | |
| Research and development | 267 | 152 | 87 | 155 | 120 | |
| General and administrative | 59 | 56 | 42 | 60 | 47 | |
| Total operating expenses | 326 | 209 | 129 | 215 | 167 | |
| Loss from operations | −326 | −200 | −126 | −215 | −167 | |
| Other income, net | 23 | 17 | 3 | 957,000 | — | |
| Total other income | 23 | 17 | 3 | 957,000 | 271,000 | |
| Net loss | −303 | −183 | −123 | −214 | −167 | |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | −13.48 | −10.21 | −18.69 | −69.65 | −3.94 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | −13.48 | −10.21 | −18.69 | −69.65 | −3.94 | |
| Weighted average common shares outstanding, basic (in shares) | 23 | 18 | 7 | 3 | 42 | |
| Weighted average common shares outstanding, diluted (in shares) | 23 | 18 | 7 | 3 | 42 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-09-30 | FY 2024 2024-06-30 | FY 2024 2024-03-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 357 | 215 | — | — | — | |
| Marketable securities | 242 | 177 | — | — | — | |
| Prepaid expenses and other current assets | 12 | 12 | — | — | — | |
| Total current assets | 611 | 404 | — | — | — | |
| Long-term marketable securities | 327 | 77 | — | — | — | |
| Property and equipment, net | 147,000 | 230,000 | — | — | — | |
| Operating lease right-of-use assets | 92,000 | 1 | — | — | — | |
| Other non-current assets | 0 | 416,000 | — | — | — | |
| Total assets | 938 | 483 | — | — | — | |
| Accounts payable | 25 | 13 | — | — | — | |
| Accrued expenses | 35 | 24 | — | — | — | |
| Operating lease liabilities | 110,000 | 1 | — | — | — | |
| Total current liabilities | 60 | 38 | — | — | — | |
| Non-current portion of operating lease liabilities | 0 | 110,000 | — | — | — | |
| Total liabilities | 60 | 38 | — | — | — | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and December 31, 2024 | 0 | 0 | — | — | — | |
| Common stock, $0.0001 par value; 150,000,000 shares authorized; 25,195,092 shares issued and outstanding as of December 31, 2025, and 19,422,358 shares issued and outstanding as of December 31, 2024 | 15,000 | 14,000 | — | — | — | |
| Additional paid-in capital | 2,018 | 1,282 | — | — | — | |
| Accumulated deficit | −1,100 | −837 | — | — | — | |
| Accumulated other comprehensive gain | 563,000 | 654,000 | — | — | — | |
| Total stockholders equity | 878 | 445 | 383 | 419 | 230 | |
| Total liabilities and stockholders equity | 938 | 483 | — | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 100,000 | 400,000 | 400,000 | 400,000 | 200,000 | |
| Stock-based compensation expense | 34 | 41 | 25 | 29 | 23 | |
| Non-cash operating lease expense | 1 | 933,000 | 837,000 | 752,000 | 1 | |
| Amortization of premiums and discounts on marketable securities, net | −4 | −5 | 47,000 | 1 | 2 | |
| Non-cash collaboration and license agreement expense | 0 | 3 | 0 | — | — | |
| Other non-cash adjustments | −7,000 | 0 | 0 | — | — | |
| Prepaid expenses and other current assets | 640,000 | −8 | 7 | 547,000 | −6 | |
| Accounts payable | 12 | 7 | −9 | 4 | 7 | |
| Accrued expenses | 11 | 16 | −8 | −10 | 15 | |
| Operating lease liabilities | −1 | −1 | −1 | — | — | |
| Deferred revenue | 0 | −3 | −2 | 5 | 0 | |
| Other | 0 | 2,000 | 0 | 56,000 | −41,000 | |
| Net cash used in operating activities | −249 | −132 | −111 | −185 | −125 | |
| Purchases of property and equipment | −56,000 | 0 | −50,000 | −444,000 | −1 | |
| Purchases of marketable securities | −624 | −372 | 0 | −83 | −164 | |
| Maturities of marketable securities | 313 | 123 | 39 | 180 | 25 | |
| Net cash (used in) provided by investing activities | −311 | −248 | 39 | 97 | −141 | |
| Payments of tax withholdings related to vesting of restricted stock units | −2 | −308,000 | −137,000 | −260,000 | 0 | |
| Proceeds from exercise of options and employee stock purchase plan purchases | 13 | 3 | 416,000 | 1 | — | |
| Net cash provided by financing activities | 702 | 514 | 92 | 10 | 108 | |
| Increase in cash, cash equivalents and restricted cash | 142 | 134 | 20 | −78 | −157 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Praxis Precision Medicines, Inc.'s CIK number?
Praxis Precision Medicines, Inc.'s SEC CIK number is 0001689548 (1689548). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Praxis Precision Medicines, Inc.'s SEC filings?
All of Praxis Precision Medicines, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Praxis Precision Medicines, Inc. last report earnings?
Praxis Precision Medicines, Inc. (PRAX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001689548-26-000049). This is Praxis Precision Medicines, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Praxis Precision Medicines, Inc.'s most recent earnings 8-K?
Praxis Precision Medicines, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001689548-26-000049. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Praxis Precision Medicines, Inc.'s latest earnings 8-K →
Look up any company's CIK number →